Gilead(US:GILD)2026-02-24 21:18Company Overview - Gilead Sciences operates in over 35 countries and focuses on innovative medicines for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer[16]. - The commercial portfolio includes more than 25 therapies, with significant advancements in HIV treatment through products like Biktarvy, Descovy, and Genvoya[18][20]. - Approximately 90% of gross product sales in the U.S. are made to three large wholesalers: Cardinal Health, Cencora, and McKesson[26]. Research and Development - Gilead's R&D efforts are concentrated on virology, oncology, and inflammation, with significant resources allocated to both internal and external development activities[29]. - A Biologics License Application for bulevirtide, targeting chronic hepatitis delta virus infection, has been filed with the FDA, receiving Orphan Drug and Breakthrough Therapy designations[32]. - Lenacapavir, an HIV-1 capsid inhibitor, is under evaluation for HIV PrEP as a once-yearly injection[32]. - A Biologics License Application has been filed with the FDA for anitocabtagene autoleucel, a CAR T-cell therapy for relapsed and/or refractory multiple myeloma patients who have received at least three prior regimens[34]. - A supplemental Biologics License Application has been filed with the FDA for sacituzumab govitecan-hziy as a first-line treatment for PD-L1 negative metastatic TNBC[34]. - Axicabtagene ciloleucel is being evaluated as a second-line treatment for high-risk FL and a first-line treatment for high-risk LBCL[34]. - Sacituzumab govitecan-hziy is being evaluated in combination with pembrolizumab for high-risk adjuvant TNBC and as a treatment for extensive stage small cell lung cancer[34]. Competition and Market Challenges - The company faces competition from large pharmaceutical firms and pricing pressures from insurers, impacting product pricing and market share[28]. - The patent for lenacapavir is set to expire in 2037 in both the U.S. and EU[38]. - The patent for bulevirtide is set to expire in 2030 in the U.S. and 2029 in the EU[38]. - The company experiences significant competition from global pharmaceutical and biotechnology companies, which affects pricing and market share[103]. - Legislative actions, such as the Inflation Reduction Act of 2022, may lead to lower negotiated Medicare prices and increased rebate obligations, negatively impacting profitability[106]. Financial Performance - Total revenues for 2025 were $29,443 million, representing a 2% increase from $28,754 million in 2024[203]. - Net income attributable to Gilead for 2025 was $8,510 million, a significant increase from $480 million in 2024, indicating a notable improvement in profitability[203]. - Diluted earnings per share attributable to Gilead rose to $6.78 in 2025, compared to $0.38 in 2024, reflecting a substantial increase in earnings per share[203]. - HIV product sales rose 6% to $20.8 billion in 2025, driven by higher demand, particularly for Biktarvy and Descovy, which saw increases of 7% and 31% respectively[210]. - Liver Disease product sales increased 6% to $3.2 billion in 2025, primarily due to higher demand for Livdelzi and chronic hepatitis products[211]. - Veklury product sales decreased 49% to $911 million in 2025, attributed to lower COVID-19-related hospitalizations[212]. - Cell Therapy product sales decreased 7% to $1.8 billion in 2025, reflecting ongoing competitive headwinds[213]. - Trodelvy product sales increased 6% to $1.4 billion in 2025, primarily due to higher demand in breast cancer treatment[214]. Employee and Corporate Responsibility - As of December 31, 2025, Gilead had approximately 17,000 employees, highlighting the company's significant human capital investment[56]. - Gilead's Total Rewards portfolio includes competitive base salary, stock awards, health and wellbeing benefits, and flexible work arrangements, aimed at optimizing employee performance[56]. - The company conducts annual pay equity reviews to ensure compensation practices are gender- and race-neutral, reflecting its commitment to addressing pay equity[57]. - Gilead's corporate responsibility strategy is overseen by the Nominating and Corporate Governance Committee, integrating ESG issues into overall business strategy[62]. Regulatory and Compliance Issues - The company faces regulatory challenges that impact product development and approval processes, which are time-consuming and costly[65]. - Gilead's operations are subject to extensive regulations, including those affecting drug pricing and reimbursement, which may impact competitiveness[66]. - The company is subject to extensive regulations governing manufacturing processes, including compliance with current Good Manufacturing Practices (cGMP) as defined by FDA and EMA, which can lead to significant delays if new suppliers need qualification[78]. - Regulatory compliance is complex, and failure to obtain timely approvals or maintain compliance could delay or halt commercialization of products[126]. - The company must navigate complex government price reporting regulations, which may lead to financial and legal liabilities if calculations are challenged[132]. Strategic Initiatives and Investments - The company is undertaking significant multi-year capital investments to expand U.S. manufacturing capabilities and accelerate R&D, with an initiative to invest $32 billion in the U.S. through 2030[164]. - The company plans to adopt and scale artificial intelligence to transform operations, indicating a focus on technological advancement[198]. - The company announced a definitive agreement to acquire Arcellx, Inc. for full control of its CAR-T cell therapy candidate, expected to close in Q2 2026[204]. Risks and Challenges - The company faces risks related to clinical trials, including potential unfavorable results and delays, which could impact the development and approval of product candidates[119]. - The company relies heavily on third-party contract research organizations (CROs) for clinical trials, which introduces risks related to control and quality of clinical data[122]. - The company is exposed to significant operational risks from global health crises, which can disrupt supply chains and impact financial performance[145]. - The company faces enhanced scrutiny over patient assistance programs, which could lead to potential legal and financial repercussions[133]. - The company has faced issues with counterfeit and illegally diverted products, which pose risks to patient safety and could harm its reputation and financial results[118].